Fermenta Biotech Ltd(FERMENTA)

NSE: FERMENTABSE: 506414

₹ 454.9-0.55%refreshed 23 Oct, 03:57 pm ISTMarket cap: ₹ 1,339 crWebsite: www.fermentabiotech.comUpdated: 24 Oct 2026

About

Fermenta Biotech makes Vitamin D3 for human and animal nutrition. It also makes other APIs and intermediates, green chemistry enzymes and environmental solutions. Reported revenue for FY26 was Rs 525.43 Cr. FY26 revenue excluding real estate was INR 546 cr, and Vitamin D3 human nutrition brought in INR 293 cr of it. Exports were 52% of turnover in FY 2024-25, going to more than 60 countries.^[1][2][3]

Business segments

Bulk drugs/chemicals was 98.2% of revenue in FY26, at Rs 514.72 Cr; it is the only reported segment.^[4]
Property revenue was Rs 54.4 Cr in FY25, against Rs 73.74 Cr in FY24.^[3][5]
Real estate contributed INR 2 cr in FY26, against INR 45 cr in FY25.^[2]
Vitamin D3 human nutrition revenue was INR 293 cr in FY26 (+28% YoY). Animal nutrition revenue was INR 109 cr (+32%).^[2]
In Q1 FY27, human nutrition D3 revenue was INR 76.5 cr, up 24% QoQ and down 10% YoY. Animal D3 revenue was INR 12.6 cr, down 41% YoY.^[6]
In Q1 FY27, Other APIs & Intermediates were INR 11.6 cr (+18% YoY), Green Chemistry/Enzymes INR 2.3 cr (+15%) and Others within nutrition INR 11 cr (+28%).^[6]

Products

The Vitamin D3 range, Phenyramidol HCl and Silicon Dry Powder made up 76% of turnover in FY25. Environmental Solutions was 5.1%.^[3]
Green Chemistry sales more than doubled to INR 16 cr in FY26 (+126% YoY).^[2]
The Indian patent for the in-house plant-based Vitamin D3 process was granted in September 2025.^[7]
VITADEE Green received FSSAI approval on 6 July 2026 for health supplements, nutraceuticals and food products.^[6]
The pipeline includes Calcifediol (including 1.25%), Penmox technology, a new lipase portfolio, Vitamin D3 analogs, lanolin derivatives, and WFP FRK and RUSF/RUTF premixes.^[2]

Operations

As of FY25, the company had 4 plants and 1 office, all in India.^[3]
Its plants include Takoli in Mandi district (Himachal Pradesh), SEZ II Dahej in Bharuch district (Gujarat) and an FRK plant at Pennepalli in Tirupati district (Andhra Pradesh).^[3]
The German toll manufacturing subsidiary's revenue was INR 65.4 cr in 9M FY26, up 147% YoY.^[8]
Subsidiaries include Fermenta Biotech GmbH (Germany), Fermenta Biotech (UK) and Fermenta Biotech USA LLC, each 100% owned, and Fermenta USA LLC, which is 52% owned.^[3]

Key operating numbers

Human nutrition D3 volumes rose 18% QoQ in Q1 FY27. They had risen 46% YoY in 9M FY26.^[6][8]
Animal nutrition volumes fell 20% YoY in Q1 FY27 and average realisation fell 40% YoY. In 9M FY26, realisation had fallen 8%.^[6][8]
Raw materials were 35% of revenue in Q1 FY27, against 37% in FY26.^[6]
Manufacturing expenses were 11% of revenue in 9M FY26, against 15% in FY25.^[8]

Customers and markets

India was 47% of revenue in Q1 FY27, against 35% a year earlier.^[6]
The FY26 revenue mix was India 39%, North America 30%, Europe 13% and others 18%. North America's share was 20% in FY24.^[2]
In FY26, the largest customer was 9% of revenue and the top 10 were 42%. 68 customers brought in INR 1-5 cr each, up from 56.^[2]
Exports were 52% of turnover in FY 2024-25, going to more than 60 countries. In India, the company serves around 20 states.^[3]
Enzyme customers include makers of oleochemicals, fine chemicals, APIs, food and fragrances, leather and biodiesel.^[3]

Expansion and capex

Calcifediol capacity is funded within the ₹110 cr Dahej capex, and its launch is nearing final validation (Q1 FY27).^[6]
Capex rose to INR 30 cr in FY26 from INR 22 cr, and inventory was built to INR 153 cr for FY27 volumes.^[2]
Stated plans include entering the EU through an EDQM CEP, selective acquisitions, and unlocking non-core real estate.^[6]

Recent developments

From 1 October 2025, the Environment Division was transferred to the wholly owned subsidiary Fermenta Environment Solutions as a slump sale, for INR 19 cr.^[7]
In FY25, Mextech was granted development rights on the remaining Thane land for residential-cum-commercial buildings.^[3]

Market Cap

₹1,339 Cr

High / Low

₹583 / 256

Stock P/E

22.6

Price / Book

3.3

Book Value

₹138

EPS

₹23.9

No. of Shares

2.94 Cr

ROCE

20.0%

ROE

18.4%

OPM

18.4%

Debt / Equity

0.27

Sales

₹525 Cr

Net Profit

₹70 Cr

Promoter holding

60.1%

Loading chart…

Signal history

AI Deep Dive

The analysis Screener can't give you

Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:

Verdict
The headline call - descriptive label, conviction, and the synthesis behind it.
Valuation
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Walk the talk
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Red flags
Forensic and governance risk pointers, severity-ranked.
Balance sheet
Solvency and earnings-quality score.
Concall briefs
Quarter-by-quarter earnings-call briefs - what changed and why.

₹49 unlocks this company for 90 days, ₹299 for a full year - bundles bring it lower. Built on public disclosures - educational, not investment advice.

AI Deep Dive

Verdict

Locked

The headline call - descriptive label, conviction, and the synthesis behind it.

Company data

Financials

Fermenta Biotech Ltd(FERMENTA)

About

Business segments

Products

Operations

Key operating numbers

Customers and markets

Expansion and capex

Recent developments

Signal history

The analysis Screener can't give you

AI Deep Dive

Verdict

Company data

Product Segments

Corporate Actions